Study to Evaluate Vectical in Combination With Clobex Spray to Treatment Plaque Psoriasis

Completed · Phase 4

Conditions studied: Psoriasis

In brief

This investigator-blinded study is designed to assess whether the order of application affects the efficacy of the combination treatment Clobex® Spray (clobetasol propionate) and Vecitcal® (calcitriol) Ointment in plaque psoriasis.

Key facts

Study ID

NCT01205880

Run by

Emer, Jason, M.D.

People needed

12

Starts

2009-12-01

Expected to finish

2010-01-01

Last updated by the study team

2010-09-21

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Subjects must be at least 18 years of age and in good general health as confirmed by a medical history.
• Females of childbearing potential must have a negative urine pregnancy test on Baseline/Day 0 and must agree to use adequate birth control methods during the entire study (a barrier method {condoms, diaphragm}; hormonal contraceptives {birth control pills, implants [Norplant] or injections [DepoProvera]}; intrauterine device {IUD}; or abstinence {no sexual activity}).
• Subjects must be diagnosed with plaque psoriasis affecting < 20% body surface area, with at least one discreet plaque on the each side of the body (excluding the face, scalp, groin, axillae or other intertriginous areas).
• Subjects must have at least 2 lesions suitable for evaluating response to test agents (one on the right side and one on the left side of the body). The severity of the disease for each target lesion at Baseline/Day 0 must be rated at least 2 (Mild) for each of the key psoriasis characteristics (scaling, erythema, and plaque elevation).
• Subjects must be able to understand the requirements of the study abide by the restrictions and return for the required examinations.

You may not qualify if…

• Female subjects who are pregnant, nursing or planning a pregnancy during the study.
• Subjects with known hypersensitivity to any components of the test medication.
• Subjects with non-plaque psoriasis (e.g. guttate, erythrodermic) or other related diseases not classified as plaque psoriasis.
• Subjects whose psoriasis involves only the scalp, face, groin, axillae, and/or other intertriginous areas.
• Subjects who have surface area involvement too large (>20% BSA) that would require more than 59 ml/week (50 g/week) of Clobex® spray and/or more than 200 g/week of Vectical® ointment.
• Subjects requiring any other medication (topical or systemic) that may affect the course of the disease during the study period as determined by the study investigators.
• Subjects using biologics or any other systemic treatment (e.g. immunosuppressants, acitretin) for psoriasis within 12 weeks of entering the study.
• Subjects using systemic corticosteroids within 28 days of entering the study
• Subjects using topical corticosteroids or other topical therapies (other than emollients) at the target area locations within 2 weeks of entering the study
• Subjects using phototherapy (UVB, PUVA) within 4 weeks of entering the study.
• Subjects with overt pre-existing telangiectasias or skin atrophy at intended treatment sites (target areas).
• Subjects with intakes of more than 2,000 IU/day (50 mcg/day) of vitamin D (tolerable upper intake level) and/or more than 1,000 mg/day of calcium (based on Dietary Reference Intakes developed by the Institute of Medicine of the National Academy of Sciences).
• Subjects who have participated in another investigational drug or device research study (at the target areas) within 30 days of enrollment.
• Subjects who are using any medication or has any disease which in the judgment of the investigator will interfere with the conduct or interpretation of the study.

Where it is running

• Mount Sinai School of Medicine — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.